Abstract
Introduction
Folate is an essential vitamin which is utilized by cells as a cofactor in purine and thymidine synthesis as well as the metabolism of methionine, homo-
. folate carrier has a low affinity K s 1-5 mM for d Ž . 5-methyltetrahydrofolate 5CH THF , the predomi-3 Ž nant form of folate found in human plasma 10-. 20 nM . Despite this relatively low concentration of plasma 5CH THF, delivery is sufficient for most 3 cells to thrive. For example, phytohaemaglutinin stimulated lymphocytes, which are receptor negative, 6 w x accumulate 40 fmol 5CH THFrhr10 cells 3 . Since 3 lymphocytes have f 600 fmol of 5CH THFr10 6 3 cells, the cells can be 'replenished' in only 15 h even if they initially had no folate. The cDNA for the putative reduced folate carrier, RFC1, has been cloned w x from mouse and hamster cells 4,5 . Based on the murine RFC1 cDNA sequence, a human homolog w x was also isolated 6-8 . Transfection of RFC1 cDNA into methotrexate resistant cells restores methotrexate w x sensitivity 4,5,7,9 .
The second mechanism for folate transport, a receptor mediated process, is initiated via binding of Ž . ligand to a glycosyl-phosphatidylinositol GPI anchored protein which has a much greater affinity than the reduced folate carrier for both reduced and oxi-Ž . dized folates K f 1 and -0. First, folate binds to the receptor followed by invagination of the plasma membrane. This 'closed' compartment is then acidified by a H q pump which reduces the affinity of folate for its receptor causing it to dissociate. The vitamin is then transported into the cell via a probenecid sensitive channel that may be the reduced folate carrier. The receptors are then exposed at the cell surface to repeat the cycle. Each of these steps can be inhibited by various compounds Ž . w x Fig. 1 12-17 . However, no compounds have yet been found to increase the rate of receptor mediated folate delivery.
This model for receptor mediated folate uptake w 3 x was based upon kinetics of H folic acid binding and w 3 x 5CH H THF uptake and polyglutamation in a near 3 confluent culture of MA104 cells, a monkey kidney w x cell line 14, 15, 17, 18 . Since the receptor is localized w x in proximal tubule cells in the kidney 19 and is present in renal cell carcinoma but not Wilm's tumor, w x the latter being an embryonic kidney tumor 20,21 , we and others have suggested that the role of the receptor is to prevent loss of folate in urine filtrate w x 22,23 . This implies that the receptor may have its greatest impact in post-mitotic, differentiated cells where its function is to facilitate specific organ or tissue delivery or uptake of the vitamin, a notion further supported by noting that folate receptor is also expressed in the epithelium of the choroid plexus and w x the syncytiotrophoblastic cells in the placenta 19 . Studies of folate receptor and folate accumulation in stationary and exponentially growing MA104 cells in w x vitro continue to support this theory 24 . Exponentially growing MA104 cells have four fold less folate receptor than mature MA104 cells and accumulate folate primarily by a receptor independent process at a rate almost two times greater than confluent cells w x 24 . However as MA104 cells mature, folate accu-Ž . Fig. 1 . Model of potocytosis: step 1-folate double ringed structure binds to folate receptors; step 2-membrane invagination; step 3-acidification; step 4-folate delivery to cytoplasm; step 5-receptors return to surface of the plasma membrane. Compoundsrconditions listed beneath model inhibit that step.
( )mulation is primarily via a receptor dependent mechanism.
In order to more completely understand the function and regulation of the folate receptor in MA104 cells, we have been searching for compounds such as hormones or drugs that affect receptor function. Here we report the effects of phorbol 12-myristate 13-Ž . acetate PMA on folate receptor location and cycling and 5-methyltetrahydrofolate uptake in confluent cells. We found that PMA causes a redistribution of the folate receptor to a predominantly external locale, increases the rate of folate receptor movement between the acid resistant and acid labile compartments and increases the rate of cytoplasmic 5-methyltetrahydrofolate accumulation. For each set, an additional flask containing 500 nM folic acid was also included in order to determine the w 3 x H -products that bound to the cell nonspecifically. After the appropriate incubation time, the cells were w x processed as previously described 24 . Briefly, the cells were chilled, rinsed twice with PBS and washed briefly with acid saline. This acid wash and following Ž . rinse were used to determine the acid labile AL Ž . fraction. The acid resistant AR fraction was determined by dissolving the cells in 0.2 N NaOH.
Materials and methods

Materials
Initial experiments using PMA at concentrations from 10 y9 to 10 y5 M confirmed a maximum effect y6 w x by 10 M 25 . Therefore, we used 1 mM PMA in all experiments unless otherwise stated. When the Ž time course of PMA activation was tested e.g. Fig. . w 3 x 2 , the cells were incubated with H FA for 3 h before the addition of PMA. When total FA binding Ž . was determined e.g. Fig. 3 , the cells were washed w 3 x twice with PBS after the H FA incubation and then NaOH was added immediately, i.e. the acid saline step was omitted.
[
] 2.2.3. 5-Methyl H tetrahydrofolate uptake
The cells were washed once with PBS followed by the addition of HBSS" 1 mM PMA and incubated 30 min at 378C unless otherwise specified. The cells w 3 x were then incubated with 20 nM 5-methyl H tetrahydrofolate. Nonspecific flasks included 6.6 mM 5CH THF. After the appropriate incubation time, the 3 w x cells were processed as previously described 24 with only minor changes. Briefly, the cells were w Ž chilled, rinsed, and then buffer A 10 mM Tris pH . 8.0 , 1% b-mercaptoethanol, and 50 nM 5-methyltex trahydrofolate was added to each flask and placed at y708C for storage until needed. The flasks were thawed on ice and the cell monolayers were scraped, rinsed, and spun at 100 000 = g. A portion of the cytosol was counted to determine total uptake. The pellet was dissolved in 0.1 N NaOH and the T25 flask was rinsed with 0.1 N NaOH and added to the pellet to determine total membrane binding. Folylpolyglutamates were separated on a reverse phase C18 column w x using a 40% acetonitrile gradient 15 . Several flasks from each experiment were trypsinized and counted on a hemocytometer to establish cell number.
] 2.2.4. Potocytosis inhibitors: 5-methyl H tetrahydrofolate assay
Cells were washed once with PBS followed by a 3 h incubation with HBSS" 10 nM FA. 1 mM PMA, 10 mM probenecid, or 25 mM monensin were then added to the appropriate flasks and the cells were incubated 30 min longer before 20 nM 5-w 3 x methyl H tetrahydrofolate was added. Nonspecific binding samples included 6.6 mM 5-methyltetrahydrofolate. The cells were incubated for 90 min at 378C before being processed for cytosol and membrane fractions as described above. 
Kinase inhibitor FA binding assay
The cells were washed once with PBS followed by w 3 x a 2.5 h incubation with 5 nM H FA. Kinase inhibitors were then added and the incubation continued for an additional 30 min before the addition of 1 mM PMA. Two hours later, AL and AR were determined as described above. When calphostin C was tested, the first 20 min of the kinase inhibitor incubation was at room temperature under ordinary fluorescent illumination.
Kinase inhibitor 5-CH THF deliÕery assay 3
Cells were washed once with PBS and incubated in HBSS" kinase inhibitors for 30 min at 378C followed by an additional 1 h incubation with 1 mM w 3 x PMA and 20 nM 5-methyl H tetrahydrofolate before being processed for cytosol and membrane fractions as described above.
The data in the figures are from representative experiments each of which was repeated at least three times in duplicate. Each value shown is the average Ž of two duplicate flasks dpmsrduplicate flasks typi-. cally varied by less than 10% with the nonspecific control already subtracted unless stated differently. Nonspecific controls for folic acid binding were f 3-4% of total counts bound. Nonspecific uptake of 5CH THF was generally 10-12% of the specific 3 uptake. When radioactivity taken up by the cell was analyzed by HPLC, ) 90% of the tritium co-chromatographed with known folate standards. is rapid 2.5% s in a cell free system at nanomolar . w x concentrations 13 , the folate receptors located in Ž . the acid labile fraction surface should be saturated within minutes. Therefore, it would be predicted that the rate limiting factor for total folate receptor saturaw 3 x tion by H FA would be receptor movement from the AR ™ AL compartment. As shown in Fig. 3 , although total membrane binding was equivalent in Ž . control and PMA treated cells 3 h time point , it appears that receptor movement from the AR ™ AL compartment was faster in PMA treated cells, because saturation occurred much more quickly than in control cells. In fact, the rate of folate receptor saturation was faster in cells pretreated with PMA for 90 min compared to only 30 min. More rapid receptor saturation was also seen if PMA was added simultaw 3 x Ž . neously with H FA data not shown . trahydrofolate was measured under control and PMA Ž . stimulated conditions. As shown in Fig. 4 A , the w 3 x initial rate of 5-methyl H tetrahydrofolate delivery Ž . was 1.8 " 0.4 n s 4 times faster in PMA treated cells compared to non-treated MA104 cells. However, after 13 h, the amount of internalized folate was equal. Therefore, PMA not only altered the ALrAR ratio and increased the rate of receptor movement, it also increased the rate of folate delivery to the cytoplasm, but not the total amount of folate accumulated.
Results
PMA treatment results in 'externalization
Shortly after 5CH THF enters the cytoplasm, it is 3 often processed into a folylpolyglutamate by the en-Ž . zyme folylpolyglutamate synthetase FPGS . This modification increases the retention of the vitamin inside the cell and its affinity for the enzymes that w x use it as a cofactor 27 . The percentages of Ž folylpolyglutamate species folylpentaglutamate and . folylheptaglutamate detected by high pressure liquid chromatography were indistinguishable between cytosols tested from control and PMA stimulated cells. w 3 x However, since 5-methyl H tetrahydrofolate uptake was increased by PMA, the amount of folylpolyglutamates synthesized was considerably larger in PMA Ž treated cells, especially at the early time points 
] 3.4. Methyl H tetrahydrofolate deliÕery is receptor mediated in PMA treated cells
We previously have shown that as MA104 cells mature, the process by which they internalize folate shifts from primarily a receptor independent, carrier mediated process to a potocyticrreceptor mediated event, and the rate of folate delivery is almost halved w x 24 . Therefore, it was important to determine if mature MA104 cells treated with PMA were reverting to a receptor independent pathway of folate delivery. There are many compounds that can differentiate Ž . between these two possibilities Fig. 1 . If mature MA104 cells are preincubated with FA to block the w 3 x folate receptor, 5-methyl H tetrahydrofolate accumulation decreases nearly 80% in both the control and Ž . PMA treated cells Fig. 5 . This provides evidence that 5CH THF uptake is largely due to a receptor 3 dependent process. Delivery was also significantly inhibited by monensin, an ionophore which presumably blocks the acidification of the closed compartw 3 x ment thereby inhibiting the release of 5-methyl H tew x trahydrofolate from the folate receptor 14 , and by probenecid, a compound known to block anion transporters. Probenecid has been shown to block both 
PMA accelerates 5CH THF deliÕery eÕen before 3 folate receptor redistribution is detected
Whether cells were incubated with PMA for 30 or w 3 x 90 min before 5-methyl H tetrahydrofolate addition, the same increased rate of folate delivery to the cytoplasm was measured. Based on this initial observation, we investigated whether redistribution of the Ž w 3 x folate receptor which is detected by H folic acid . binding 30-90 min after PMA addition was necessary for the increased rate of 5-methyltetrahydro-Ž . folate delivery to the cytoplasm Fig. 6 . As expected Fig. 2 , when PMA and H FA were added simultaneously, no significant increase in the acid labile folate receptor population was measured at 30 min. However by 20 min, the cytoplasmic content w 3 x of 5-methyl H tetrahydrofolate in cells co-incubated with PMA was increased 50% over the control cells and by 30 min, by 75%.
PMA effect may not be mediated by PKC
Under most circumstances, PMA binds to and then activates members of the conventional and novel protein kinase C enzyme families. Within the last several years, two other proteins, n-chimaerin and the C. elegans protein Unc-13, have been shown to possess high affinity binding sites for phorbol esters w x as well 29 . In order to determine if PMA was Ž . binding to and activating a member s of the PKC family, we screened a series of PKC inhibitors with different degrees of kinase specificity and sites of w x inhibitory action 30,34 . Cells were incubated with inhibitors for 30 min before the addition of PMA. After an additional 2 h incubation, folate receptor Ž . distribution was measured Fig. 7 . As shown previ-Ž . ously Figs. 2 and 6 , incubation with PMA results in a redistribution of the receptor such that approximately 70% is in the acid labile fraction. Only 100 nM staurosporine completely blocks the effect of PMA, although 500 mM H-7 inhibits a significant amount of receptor redistribution as well. These two inhibitors are not very specific for PKC; they bind to the ATP w x binding site of many kinases 30,35 . Bisindolylmaleimides are analogs of staurosporine and have been shown to be more potent inhibitors of PKC w x compared to other kinases 30 . Here bisindolylmaleimide VIII was less effective than staurosporine. Chelerythrine also has more selectivity for PKC comw x pared to other kinases 30,46 ; however it did not inhibit the folate receptor redistribution caused by PMA. Finally calphostin C, a compound designed to bind to the regulatory domain of PKC and competitively inhibit PMA binding also had no inhibitory w x effects in our assay 30,46 . This experiment was also Ž . done at lower PMA concentrations 0.25-0.35 mM with no qualitative changes in the results. Moreover, these inhibitors had no effect on folate receptor distribution when added alone. Based on these data, we believe activation of PKC by PMA is not responsible for folate receptor redistribution.
Additional studies have suggested to us that staurosporine may be inhibiting an event downstream of the PMA target because staurosporine can be added subsequent to maximal PMA activity and still reverse the folate receptor redistribution back to control lev-Ž . els data not shown . Other drugs such as forskolin Ž . w x and Bt cAMP protein kinase A activators , KN-62 2 w x w and W7 CaM kinase II inhibitors , genistein general x w tyrosine kinase inhibitor , wortmannin PI3 kinase x w x inhibitor , and anisomycin SAP kinase activator were screened to see if they would mimic or inhibit the folate receptor redistribution caused by PMA in hopes of identifying known signalling proteins that may be involved in this pathway. None had any effect. Therefore, we currently have no leads to the signal transduction events that are causing this folate receptor redistribution.
The effect of the inhibitors on PMA stimulated 5CH THF delivery were quite different from those 3 Ž . seen on receptor redistribution Fig. 8 . Stelazine, thorazine, H-7, and chelerythrine completely inhibited the stimulatory effect of PMA. Staurosporine and calphostin C could only partially inhibit this effect, and bisindolylmaleimide VIII was completely inef-Ž . fective. In the control s for this experiment, the PKC inhibitors incubated with the cells in the absence of PMA, revealed that only 50 mM chelethryine had any Ž . inhibitory effect data not shown . Thus the inhibition of the PMA effect seen with the other drugs seems to be specific for the PMA mediated component, but not for ''basal'' folate receptor function. Fig. 7 . Effect of PKC inhibitors on PMA stimulated FR redistribution. Cells were treated with 5 nM H FA for 2.5 h followed by the Ž addition of PKC inhibitors 100 nM staurosporine, 500 mM H-7, 78 mM thorazine, 56 mM stelazine, 500 nM bisindolylmaleimide VIII, . 50 mM chelerythrine, or 750 nM calphostin C . Thirty minutes later, 1 mM PMA was added and the cells harvested for AL and AR 2 h Ž .
Ž . later. A shows total binding subdivided into AL and AR components, B shows ALrAR ratio. Triplicate specific plates were used for each condition; error bars denote the SEM. . trahydrofolate delivery pmolr10 cells was measured as described in Section 2 after a 60 min incubation. Triplicate specific plates were used for each condition; error bars denote the SEM.
Discussion
FRa , the only folate receptor isoform expressed in MA104 cells, has a very limited tissue distribution which includes the choroid plexus, kidney and placenta and excludes liver, muscle, brain and lymphow x cytes 3,19,31 . It is also up-regulated in many maligw x nant cancers of epithelial origin 20 . In order to more completely understand the function of FRa , we have expanded our studies of folic acid binding and 5CH THF uptake originally done in near confluent 3 MA104 cells to include exponential and stationary phase MA104 cells. We previously reported that w 3 x H thymidine labeling and 5CH THF uptake rates 3 were directly related, but were inversely related to quantity of folate receptor, i.e. folate receptor is not w x required during rapid growth 24 . Here we have more completely studied folate receptor movement and 5CH THF uptake in confluent non-mitotic cells 3 and have identified the first activator of potocytosis.
We have shown that PMA significantly alters the ALrAR ratio of folate receptors. Under normal conditions, only 1r3 of the folate receptors are located Ž . on the surface of the plasma membrane AL , and 2r3 of the receptors are in an internal acid-resistant Ž . compartment AR , that is to say ALrAR is 0.5. Incubation with PMA drastically altered the distribution of folate receptors so that f 70% of the receptors are now located on the surface of the plasma Ž . membrane Fig. 2 . We are not able to directly measure the AR ™ AL folate receptor movement rate without perturbing the cells significantly by an acid ( )Ž . wash or drastic temperature changes 4 ™ 378C . The increased rate of folate receptor movement is likely the reason that the total folate receptor pool in PMA w 3 x treated cells is labeled faster with H FA compared Ž . to control cells Fig. 3 . Moreover, receptor movement from the AL to AR compartment measured w 3 x Ž within the first 5 min of H FA addition to insure . measurement of only unidirectional movement is also accelerated approximately two fold in cells pretreated with PMA for 30 min.
In addition to increased receptor movement, an increased rate of delivery and metabolism of 5-w 3 x methyl H tetrahydrofolate was found. This uptake was blocked by compounds known to inhibit various steps in the potocytic process. PMA is the first compound we have found that accelerated receptor mediated delivery; all previous compounds that al-Ž . tered the process were inhibitors Fig. 1 .
These results are in partial contradiction to the recently reported effects of PMA on MA104 cells w x cultured only for 5 days 25 . In these studies, PMA caused the folate receptor to shift to the cell surface, w 3 x but 5-methyl H tetrahydrofolate delivery to the cytoplasm was inhibited. We have not been able to w 3 x reproduce the inhibition of 5-methyl H tetrahydrofolate uptake by day 5 MA104 cells grown under the conditions described here or those described previw x ously 25 . In our hands, PMA does not affect delivw 3 x ery of 5-methyl H tetrahydrofolate in day 5 cells but it does externalize the vast majority of the receptor. One possible explanation for the differences between the response of day 5 and 8 cells to PMA may be the maturation of the cells which results in as yet undefined but different signal transduction pathways being operative. Since increased 5CH THF delivery can be We suspect that PKC is not mediating the effects of PMA. A wide range of PKC inhibitors, varying in their specificities to inhibit PMA binding or kinase activation, did not block the effect of PMA on folate Ž . receptor redistribution Fig. 7 . The only compounds that inhibited the effect of PMA were 500 mM H-7 and 100 nM staurosporine. At this concentration of Ž . H-7 5-50 times its IC50 value , we assume it is not acting specifically as a PKC inhibitor. Other proteins known to bind phorbol esters such as Unc-13 and w x n-chimaerin 29,32,33 should have been inhibited by calphostin C, which binds to the phorbol ester binding site on these proteins as well as the PKC family.
Even though staurosporine inhibited folate receptor redistribution caused by PMA at predicted IC50 concentrations, staurosporine inhibits other seriner threonine and tyrosine kinases such as protein kinase A, cGMP dependent protein kinase, and myosin light w x chain kinase at similar concentrations 30,34 . More specific PKC inhibitor analogs of staurosporine exist such as bisindolylmaleimide VIII; this compound which is 10-100 times more specific for PKC than w x PKA 35 did not inhibit the folate receptor redistribution caused by PMA.
The inhibitory effect of chelethryine on folate delivery even in the absence of PMA, but not receptor distribution may be a more important lead with respect to non-receptor initiated but carrier mediated folate uptake because the recently cloned reduced Ž . folate carrier RFC has several consensus PKC sites. In this regard, it should be noted that Said and colleagues did not see an inhibitory effect of some PKC and PKA inhibitors on RFC mediated uptake in intestinal cells but did note that a protein tyrosine Ž . kinase inhibitor genistein inhibited folate uptake by w x decreasing the apparent V 46 . This molecule did max not block transport in MA104 cells. Additional studies are clearly needed to sort out the control mechanisms operative for folate accumulation via either pathways. Based upon comparing the effects of some of these compounds on the same cells at different stages of confluence as well as different cell types Ž e.g. hepatocytes, intestinal cells, kidney epithelial . cells and murine leukemiarlymphoma cells it seems reasonable to assume that different regulatory pathways most likely exist.
Ž . Other PKC agonists such as y indolactam V and phorbol 12,13 dibutyrate were equally effective in Ž our system and the PKC inactive analogs 4a-PMA, Ž .
. q indolactam V and 4a-phorbol 12,13 dibutyrate had no stimulatory effects in our system. Based upon these stereospecific structureractivity results, we hypothesize that PMA is binding and activating a novel Ž . protein s that contains a domain similar to the dia-( )cylglycerolrphorbol ester binding domain found in the protein kinase C family.
Since the folate receptor may be a useful immunological target or means of targeting drug delivery Ž w x. Ž . reviewed in 10 elucidating mechanisms means for altering its function in normal and malignant cells is important if there is to be an increased therapeutic efficacy with regard to selective delivery of antifolates. The work here coupled with our previous w x Ž studies 21,24,36-38 and the work of others e.g. w x. 39,40 reminds us that it is important to study the function and regulation of the folate receptor in multiple models, because receptor functionrmalfunction and modulation seems dependent on both cell lineage and cell density or state of differentiation. The effects seen here may also be applicable to other GPI anchored proteins which appear to distribute into multiw x ple compartments in the membrane 41-45 . 
